Publications by authors named "Jonathan Roos"

Claim this Profile
H
Human glucocerebrosidase mediates formation of xylosyl-cholesterol by β-xylosidase and transxylosidase reactions.
Daphne E Boer, Mina Mirzaian, Maria J Ferraz, Kimberley C Zwiers, Merel V Baks, Jonathan C P Roos

J Lipid Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on: Epimax-related ocular surface toxicity (EROST): the Glasgow experience.
Amy Gallant Sullivan, Rachna Murthy, Jonathan C P Roos

Eye (Lond)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time requirements for perioperative glucose management using fully closed-loop versus standard insulin therapy: A proof-of-concept time-motion study.
Jonathan Roos, Daniel Schürch, Andreas Frei, Sophie Lagger, Matthias Schwenkglenks

Diabet Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TFOS Lifestyle: Impact of cosmetics on the ocular surface.
David A Sullivan, Alexandre X da Costa, Ester Del Duca, Tracy Doll, Christina N Grupcheva, Jonathan Roos

Ocul Surf· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of the Dexcom G6 Continuous Glucose Monitoring System During Cardiac Surgery Using Hypothermic Extracorporeal Circulation.
David Herzig, Martina Vettoretti, Dominik P Guensch, Andreas Melmer, Daniel Schürch, Jonathan Roos

Diabetes Care· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thyrotropin Receptor Autoantibody Assessment in Thyroid Eye Disease: Does the Assay Type Matter?
Malik Moledina, Jonathan Roos, Rachna Murthy

Korean J Ophthalmol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery.
Gabija Krutkyte, Jonathan Roos, Daniel Schuerch, Cecilia Czerlau, Malgorzata E Wilinska

Diabetes Technol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative Fully Closed-Loop Insulin Delivery in Patients Undergoing Elective Surgery: An Open-Label, Randomized Controlled Trial.
David Herzig, Simon Suhner, Jonathan Roos, Daniel Schürch, Luca Cecchini

Diabetes Care· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Fibrotic Contraction by Sirolimus (Rapamycin) in an Ex Vivo Model of Thyroid Eye Disease.
Jonathan C P Roos, Viesturs Eglitis, Rachna Murthy

Ophthalmic Plast Reconstr Surg· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teprotumumab for Active Thyroid Eye Disease.
Jonathan C P Roos, Hanna I Hyry, Rachna Murthy

N Engl J Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Periocular hyaluronic acid fillers: applications, implications, complications.
Rachna Murthy, Jonathan C P Roos, Robert A Goldberg

Curr Opin Ophthalmol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on the clinical assessment and management of thyroid eye disease.
Jonathan C P Roos, Rachna Murthy

Curr Opin Ophthalmol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both.
Hanna I Hyry, Jonathan C P Roos

Eye (Lond)· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves' orbitopathy.
Jonathan C P Roos, Rachna Murthy

Eye (Lond)· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ophthalmic manifestations of Gaucher disease: the most common lysosomal storage disorder.
Aaron W Winter, Ali Salimi, Luis H Ospina, Jonathan C P Roos

Br J Ophthalmol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy.
Jonathan C P Roos, Vignesh Paulpandian, Rachna Murthy

Eye (Lond)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.
Jonathan C P Roos, Carla Moran, V Krishna Chatterjee, Joanne Jones, Alasdair Coles

Eye (Lond)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T2-relaxation mapping and fat fraction assessment to objectively quantify clinical activity in thyroid eye disease: an initial feasibility study.
Tilak Das, Jonathan C P Roos, Andrew J Patterson, Martin J Graves, Rachna Murthy

Eye (Lond)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on: A British Ophthalmic Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom.
Jonathan C P Roos, Rachna Murthy

Eye (Lond)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outrageous prices of orphan drugs: a call for collaboration.
Lucio Luzzatto, Hanna I Hyry, Arrigo Schieppati, Enrico Costa, Steven Simoens, Jonathan C P Roos

Lancet· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply Re: "Can We Improve the Tolerance of an Ocular Prosthesis by Enhancing Its Surface Finish?".
Andre S Litwin, Emma Worrell, Jonathan C P Roos, Barry Edwards, Raman Malhotra

Ophthalmic Plast Reconstr Surg· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can We Improve the Tolerance of an Ocular Prosthesis by Enhancing Its Surface Finish?
Andre S Litwin, Emma Worrell, Jonathan C P Roos, Barry Edwards, Raman Malhotra

Ophthalmic Plast Reconstr Surg· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management.
Jonathan C P Roos, Matthew J Daniels, Elizabeth Morris, Hanna I Hyry, Timothy M Cox

Mol Genet Metab· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brexit and rare diseases: big risk, bigger opportunity?
Hanna I Hyry, Timothy M Cox, Jonathan C P Roos

Curr Med Res Opin· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Let's hear it for the case report.
Jonathan Roos

BMJ· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis